Invitris
PrivateLast Round
Grant
Feb 17, 2025
Est. Valuation
$1.79M
Total Funding Raised
$3.34M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Invitris operates in Healthcare & Life Sciences and is based in Munich. Its latest recorded funding round was a Grant round in February 2025.
Invitris is a biotechnology company that develops a cell-free protein expression platform called Phactory™ to manufacture therapeutic proteins, including bacteriophages, to combat antibiotic-resistant infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Invitris Comparables
Compare Invitris with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| LenioBio | 83% | |
| BioLinker | 80% | |
| Tierra Biosciences | 79% |
For institutional investors. Book with your work email.
Invitris Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 17, 2025 | ||||
| Accelerator | Dec 19, 2024 | ||||
| Grant | May 9, 2023 | ||||
| Accelerator | Mar 10, 2023 | ||||
| Grant | Jan 27, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Invitris Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Accelerator, Grant |
| INCATE | Grant |
| Y Combinator | Accelerator |
| another.vc | Accelerator |
| 10x Founders | Accelerator |
| Mergus Ventures | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 928% MoM, from 157 to 1.6K.
- May 16, 2026
Monthly visitors increased 1403% from 61 to 917.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 22, 2026
Invitris is developing a cell-free platform in Germany that turns digital sequences into proteins, antibodies and phages within hours.
For institutional investors. Book with your work email.
Invitris Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Invitris's valuation, stock price, and market status.
Is Invitris a public or private company?
Invitris is a private company.
What is the current stock price of Invitris?
Invitris is a private company, so its shares have no public market price. Caplight tracks Invitris's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Invitris worth (valuation)?
Invitris's valuation is estimated at $1.8M based on funding round data.
Can I buy Invitris stock?
Invitris shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Invitris's last funding round?
Invitris's most recent funding round was Grant on February 17, 2025.
Who are the main investors in Invitris?
Key investors in Invitris include European Innovation Council Fund, INCATE.
Will Invitris IPO soon?
No public IPO plans have been announced for Invitris.
How can I track Invitris secondary market activity?
Caplight tracks bids, offers, and trades in Invitris's shares on secondary markets.